logo
  Join        Login             Stock Quote

Curis (CRIS): U.S. Patent Issuance Covering HSP90 Inhibitor Debio 0932

 December 06, 2012 08:07 AM
 


(By Balaseshan) Curis Inc. (NASDAQ: CRIS), a drug discovery and development company, announced the U.S. patent issuance covering Heat Shock Protein 90 (HSP90) inhibitor Debio 0932.

The U.S. Patent and Trademark Office has issued a patent covering a genus of compounds that includes Debio 0932, an orally-administered Heat Shock Protein 90 (HSP90) inhibitor, which is being developed by Curis' licensee Debiopharm.

The newly issued patent, U.S. Patent Number 8,324,240, is entitled "Fused Amino Pyridine as HSP90 Inhibitors".

Debio 0932 is an oral second-generation HSP90 inhibitor, which has shown extended tumour retention, blood-brain-barrier penetration, and promising anti-tumour activity both as monotherapy and in combination against a broad range of tumours in pre-clinical models.

[Related -Curis (CRIS), Debiopharm Initiate Advanced Non-Small Cell Lung Cancer Study]

"We believe that this patent issuance recognizes the novelty of Debio 0932, a molecule that was invented internally by Curis scientists. We have been pleased with Debiopharm's development efforts and the clinical data generated to-date," stated Dan Passeri, Curis' President and Chief Executive Officer.

Debiopharm presented data from the dose escalation portion of an ongoing Phase 1 clinical trial study at the annual meeting of the American Society of Clinical Oncology in June 2012. Debio 0932 was generally well tolerated in this study and showed promising signs of anti-tumour activity in patients with advanced solid tumours, especially lung cancer.

[Related -Top 10 Oncology Drugs Available For Partnering (Part II)]

Curis is looking forward to additional data from this promising molecule, as Debiopharm is currently testing Debio 0932 in a Phase 1/2 clinical trial in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) as well as in a Phase 1b clinical study in patients with solid tumors, including NSCLC.

Debiopharm also plans to initiate a separate Phase 1/2 clinical trial with Debio 0932 in combination with Everolimus in patients with renal cell carcinoma in the second half of 2013.

CRIS closed Wednesday's regular session down 2.48% at $3.14. The stock has been trading between $3.02 and $5.65 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageHow the Chinese Slowdown Will Impact Your Investments

Most countries would find a quarterly growth rate of 7.3% a cause for a read on...

article imageHow To Profit From Foreign Investment In Real Estate

Though investors don't always capitalize on it, history has a way of repeating itself. In fact, when I saw read on...

article imageAnother Round Of Upbeat US Macro Reports

The US economy grew faster than expected in this year’s third quarter, according to this morning’s read on...

article imageDistinguishing The Fed's Securities Purchases From Monetary Expansion

There has been a bit of confusion about what today's FOMC announcement means with respect to Quantitative read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Indices Close Ahead On Afternoon Comeback
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.